Health
Ultrapotent compound may help treat C. diff, reduce recurrence – Medical Xpress
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Only two antibiotics, vancomycin and fidaxomicin, are FDA approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.
Now, Purdue University innovators have advanced novel compounds they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Preventio…
-
Noosa News19 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense
-
Noosa News22 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
Noosa News19 hours agoHomicide investigation underway after woman found dead in north Brisbane
-
Noosa News12 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane